Literature DB >> 3172582

Endogenous endotoxemia in patients with liver cirrhosis--a quantitative analysis of endotoxin in portal and peripheral blood.

G Tachiyama1, M Sakon, J Kambayashi, S Iijima, T Tsujinaka, T Mori.   

Abstract

In order to investigate the mechanism of endogenous endotoxemia (that is, endotoxemia observed in the absence of infection) in patients with liver cirrhosis, the concentration of endotoxin in the portal (PO-Et) and peripheral blood (PE-Et) from fifty three patients undergoing abdominal surgery was simultaneously measured by a quantitative endotoxin assay. The PE-Et of the patients with liver cirrhosis (19.8 +/- 20.2 pg/ml, n = 23) was significantly elevated, when compared with that of the patients without liver cirrhosis (9.2 +/- 5.1 pg/ml, n = 30), and was close to the normal range of PE-Et obtained from thirty healthy volunteers (7.2 +/- 4.1 pg/ml, n = 30). The PO-Et was also higher in the patients with liver cirrhosis than in the patients without liver cirrhosis. Moreover, PO-Et was significantly higher than PE-Et in all the patients (p less than 0.05). The per cent difference in the endotoxin concentration between the portal and peripheral blood (percentage of delta Et) was significantly decreased in the cirrhotic patients, especially in those with esophageal varices, which was well correlated with the phagocytic activity of the reticuloendothelial system (RES) determined by the clearance of iron colloid. The endogenous endotoxemia is thus likely to be due to the impaired clearance of endogenous endotoxin in portal blood, resulting from both the decreased phagocytic activity of RES in the liver and the coexisting porta-systemic bypass.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3172582     DOI: 10.1007/bf02471464

Source DB:  PubMed          Journal:  Jpn J Surg        ISSN: 0047-1909


  27 in total

1.  THE ROLE OF ENDOTOXIN IN THE EXTRACELLULAR COAGULATION OF LIMULUS BLOOD.

Authors:  J LEVIN; F B BANG
Journal:  Bull Johns Hopkins Hosp       Date:  1964-09

2.  Detection of endotoxin in plasma and ascitic fluid of patients with cirrhosis: its clinical significance.

Authors:  K Tarao; K So; T Moroi; T Ikeuchi; T Suyama
Journal:  Gastroenterology       Date:  1977-09       Impact factor: 22.682

3.  The Limulus test in experimental and clinical endotoxaemia.

Authors:  D P Fossard; V V Kakkar
Journal:  Br J Surg       Date:  1974-10       Impact factor: 6.939

4.  Effect of cholestyramine on endotoxin toxicity and absorption.

Authors:  J P Nolan; M V Ali
Journal:  Am J Dig Dis       Date:  1972-02

5.  Relation of renal impairment and haemorrhagic diathesis to endotoxaemia in fulminant hepatic failure.

Authors:  S P Wilkinson; V Arroyo; B G Gazzard; H Moodie; R Williams
Journal:  Lancet       Date:  1974-03-30       Impact factor: 79.321

6.  The clearance, tissue distribution, and cellular localization of intravenously injected lipopolysaccharide in rabbits.

Authors:  J C Mathison; R J Ulevitch
Journal:  J Immunol       Date:  1979-11       Impact factor: 5.422

7.  Chromogenic substrates for horseshoe crab clotting enzyme. Its application for the assay of bacterial endotoxins.

Authors:  S Iwanaga; T Morita; T Harada; S Nakamura; M Niwa; K Takada; T Kimura; S Sakakibara
Journal:  Haemostasis       Date:  1978

8.  Addition of perchloric acid to blood samples for colorimetric limulus test using chromogenic substrate: comparison with conventional procedures and clinical applications.

Authors:  T Obayashi
Journal:  J Lab Clin Med       Date:  1984-09

9.  Portal venous and systemic endotoxaemia in patients without liver disease and systemic endotoxaemia in patients with cirrhosis.

Authors:  H Prytz; J Holst-Christensen; B Korner; H Liehr
Journal:  Scand J Gastroenterol       Date:  1976       Impact factor: 2.423

10.  Clearance capacity of rat liver Kupffer, Endothelial, and parenchymal cells.

Authors:  D P Praaning-van Dalen; A Brouwer; D L Knook
Journal:  Gastroenterology       Date:  1981-12       Impact factor: 22.682

View more
  11 in total

Review 1.  Pathogenesis of ascites and hepatorenal syndrome.

Authors:  S P Wilkinson; K P Moore; V Arroyo
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

Review 2.  Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia.

Authors:  Hiroshi Fukui
Journal:  World J Hepatol       Date:  2015-03-27

Review 3.  Alcohol, inflammation, and gut-liver-brain interactions in tissue damage and disease development.

Authors:  H Joe Wang; Samir Zakhari; M Katherine Jung
Journal:  World J Gastroenterol       Date:  2010-03-21       Impact factor: 5.742

4.  A new method for the quantification of beta-glucan in plasma and its application in the diagnosis of postoperative infection.

Authors:  M Yokota; J Kambayashi; T Tsujinaka; M Sakon; T Mori; M Tsuchiya; H Oishi; S Matsuura
Journal:  Jpn J Surg       Date:  1990-09

5.  The Clinical Impact of Cirrhosis on the Hospital Outcomes of Patients Admitted With Influenza Infection: Propensity Score Matched Analysis of 2011-2017 US Hospital Data.

Authors:  David U Lee; Gregory H Fan; David J Hastie; Vibhav N Prakasam; Elyse A Addonizio; Ryan R Ahern; Kristen J Seog; Raffi Karagozian
Journal:  J Clin Exp Hepatol       Date:  2021-02-04

6.  Attenuation of congenital portosystemic shunt reduces inflammation in dogs.

Authors:  Michael S Tivers; Ian Handel; Adam G Gow; Victoria J Lipscomb; Rajiv Jalan; Richard J Mellanby
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

7.  Lipopolysaccharide inhibits myogenic differentiation of C2C12 myoblasts through the Toll-like receptor 4-nuclear factor-κB signaling pathway and myoblast-derived tumor necrosis factor-α.

Authors:  Yuko Ono; Kazuho Sakamoto
Journal:  PLoS One       Date:  2017-07-24       Impact factor: 3.240

Review 8.  Gut Microbiome-based Therapeutics in Liver Cirrhosis: Basic Consideration for the Next Step.

Authors:  Hiroshi Fukui
Journal:  J Clin Transl Hepatol       Date:  2017-06-29

Review 9.  Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far?

Authors:  Hiroshi Fukui
Journal:  Diseases       Date:  2019-11-12

10.  TAK-242, a specific inhibitor of Toll-like receptor 4 signalling, prevents endotoxemia-induced skeletal muscle wasting in mice.

Authors:  Yuko Ono; Yuko Maejima; Masafumi Saito; Kazuho Sakamoto; Shoichiro Horita; Kenju Shimomura; Shigeaki Inoue; Joji Kotani
Journal:  Sci Rep       Date:  2020-01-20       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.